Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Redburn Atlantic analyst Joshua Smith initiated coverage of Ionis Pharmaceuticals (IONS) with a Neutral rating and $39 price target Ionis is a ...

Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.

NewSound, a leading innovator in hearing aids with over two decades of expertise, today launched its first truly AI-driven over-the-counter hearing aid, powered by Femtosense's AI Acceleration.

Camunda, the leader in process orchestration and automation, will host its CamundaCon 2025 Amsterdam conference, at Beurs van Berlage in Amsterdam, on May 14 and 15, 2025. The event will highlight why ...

Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® ...

Theratechnologies Inc.’s THTX share price has surged by 20.78%, which has investors questioning if this is right time to sell ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

On Wednesday, 12 March 2025, Ionis Pharmaceuticals (NASDAQ: IONS) presented at the Barclays 27th Annual Global Healthcare Conference. The discussion, led by CFO Beth Hogan, showcased the company’s ...

Ionis Pharma's Tryngolza (olezarsen) has become the first FDA-approved drug therapy for adults with rare disease familial chylomicronaemia syndrome. Patients with the rare disease familial ...